{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T15:02:58Z","timestamp":1791471778783,"version":"4.3.4"},"reference-count":38,"publisher":"Oxford University Press (OUP)","issue":"4","license":[{"start":{"date-parts":[[2018,4,1]],"date-time":"2018-04-01T00:00:00Z","timestamp":1522540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/501100000545","name":"British Association of Dermatologists","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000545","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,4,1]]},"abstract":"<jats:title>Summary<\/jats:title><jats:sec><jats:title>Aim<\/jats:title><jats:p>Blauvelt et al. aimed to compare the long-term efficacy and safety of dupilumab with medium-potency topical corticosteroids (TCS) vs. placebo with TCS in adults with moderate-to-severe atopic dermatitis (AD).<\/jats:p><\/jats:sec><jats:sec><jats:title>Setting and design<\/jats:title><jats:p>This multicentre randomized, double-blinded, placebo-controlled trial was conducted in hospitals, clinics and academic institutions across 161 sites in 14 countries.<\/jats:p><\/jats:sec><jats:sec><jats:title>Study exposure<\/jats:title><jats:p>Adults with moderate-to-severe AD were randomly assigned (3: 1: 3) to receive subcutaneous dupilumab 300 mg once weekly plus TCS, dupilumab 300 mg every 2 weeks plus TCS or placebo plus TCS until week 52.<\/jats:p><\/jats:sec><jats:sec><jats:title>Outcomes<\/jats:title><jats:p>Co-primary efficacy end points were percentage of patients achieving Investigator's Global Assessment (IGA) 0\/1 and 2 points or higher improvement from baseline, and Eczema Area and Severity Index 75% improvement from baseline (EASI-75) at week 16.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>In total, 740 patients were included in the trial: 319 were randomly assigned to dupilumab once weekly, 106 to dupilumab every 2 weeks and 315 to the placebo arm. At week 16, more patients in the dupilumab groups achieved the co-primary end points: IGA 0\/1 [39% (n = 125) once-weekly dosing, 39% (n = 41) every 2 weeks dosing vs. 12% (n = 39) receiving placebo; P &amp;lt; 0\u00b70001] and EASI-75 [64% (n = 204) and 69% (n = 73) vs. 23% (n = 73); P &amp;lt; 0\u00b70001]. While no new safety signals were identified, adverse effects were noted in 261 (83%) of those receiving dupilumab once weekly plus TCS, 97 (88%) receiving dupilumab every 2 weeks plus TCS and 266 (84%) for those receiving placebo plus TCS. Rates of conjunctivitis, injection site reactions and local herpes simplex infections were higher in the dupilumab groups than in the placebo group.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions<\/jats:title><jats:p>Blauvelt et al. concluded that dupilumab treatment added to TCS improved AD up to week 52 vs. TCS alone, and also demonstrated acceptable safety.<\/jats:p><\/jats:sec>","DOI":"10.1111\/bjd.16317","type":"journal-article","created":{"date-parts":[[2018,1,10]],"date-time":"2018-01-10T13:02:26Z","timestamp":1515589346000},"page":"897-902","source":"Crossref","is-referenced-by-count":26,"title":["Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a critical appraisal"],"prefix":"10.1093","volume":"178","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6644-0979","authenticated-orcid":false,"given":"J.","family":"Thomson","sequence":"first","affiliation":[{"name":"Department of Dermatology The Royal London Hospital Barts Health NHS Trust London U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5920-6888","authenticated-orcid":false,"given":"A.G.H.","family":"Wernham","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Hospitals Birmingham NHS Trust Birmingham U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.C.","family":"Williams","sequence":"additional","affiliation":[{"name":"Centre of Evidence Based Dermatology King's Meadow Campus Nottingham U.K"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,4,1]]},"reference":[{"key":"2023011316192025600_bjd16317-bib-0001","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1016\/j.jaci.2013.08.031","article-title":"Adult eczema prevalence and associations with asthma and other health and demographic factors: a US population-based study","volume":"132","author":"Silverberg","year":"2013","journal-title":"J Allergy Clin Immunol"},{"key":"2023011316192025600_bjd16317-bib-0002","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1111\/jdv.12784","article-title":"Adult eczema in Italy: prevalence and associations with environmental factors","volume":"29","author":"Pesce","year":"2015","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023011316192025600_bjd16317-bib-0003","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/j.1365-2133.2012.10904.x","article-title":"Eczema among adults: prevalence, risk factors and relation to airway diseases. Results from a large-scale population survey in Sweden","volume":"166","author":"R\u00f6nmark","year":"2012","journal-title":"Br J Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0004","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1080\/09546634.2016.1174765","article-title":"Addressing treatment challenges in atopic dermatitis with novel topical therapies","volume":"27","author":"Silverberg","year":"2016","journal-title":"J Dermatol Treat"},{"key":"2023011316192025600_bjd16317-bib-0005","first-page":"260","article-title":"Quality of life in atopic dermatitis patients","volume":"40","author":"Mozaffari","year":"2007","journal-title":"J Microbiol Immunol Infect"},{"key":"2023011316192025600_bjd16317-bib-0006","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1111\/j.1468-3083.2012.04636.x","article-title":"Guidelines for treatment of atopic eczema (atopic dermatitis) Part II","volume":"26","author":"Ring","year":"2012","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023011316192025600_bjd16317-bib-0007","doi-asserted-by":"crossref","first-page":"1617","DOI":"10.1111\/bjd.15235","article-title":"Treatment of moderate-to-severe atopic eczema in adults within the UK: results of a national survey of dermatologists","volume":"176","author":"Taylor","year":"2017","journal-title":"Br J Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0008","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1016\/j.jaci.2013.07.049","article-title":"Efficacy and safety of systemic treatments for moderate-to-severe atopic dermatitis: a systematic review","volume":"133","author":"Roekevisch","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2023011316192025600_bjd16317-bib-0009","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1016\/j.jaad.2014.03.030","article-title":"Guidelines of care for the management of atopic dermatitis: section 3. Management and treatment with phototherapy and systemic agents","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0010","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1111\/j.1365-2133.1994.tb02936.x","article-title":"Maintenance treatment with cyclosporin in atopic eczema","volume":"130","author":"Munro","year":"1994","journal-title":"Br J Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0011","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1016\/0140-6736(91)90134-B","article-title":"Double-blind, controlled, crossover study of cyclosporin in adults with severe refractory atopic dermatitis","volume":"338","author":"Sowden","year":"1991","journal-title":"Lancet"},{"key":"2023011316192025600_bjd16317-bib-0012","doi-asserted-by":"crossref","first-page":"634","DOI":"10.1111\/j.1365-2133.1994.tb13111.x","article-title":"Cyclosporin in atopic dermatitis: a multicentre placebo-controlled study","volume":"130","author":"Joost","year":"1994","journal-title":"Br J Dermatol"},{"issue":"1","key":"2023011316192025600_bjd16317-bib-0013","first-page":"CD007893","article-title":"Effect of cyclosporine on blood pressure","author":"Robert","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"2023011316192025600_bjd16317-bib-0014","first-page":"421","article-title":"Cyclosporin-A associated malignancy","volume":"1","author":"Durnian","year":"2007","journal-title":"Clin Ophthalmol"},{"key":"2023011316192025600_bjd16317-bib-0015","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1111\/j.1468-3083.2006.02023.x","article-title":"Cyclosporin in the treatment of patients with atopic eczema\u2013a systematic review and meta-analysis","volume":"21","author":"Schmitt","year":"2007","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023011316192025600_bjd16317-bib-0016","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1016\/j.jaad.2014.08.038","article-title":"Guidelines of care for the management of atopic dermatitis: Section 4. Prevention of disease flares and use of adjunctive therapies and approaches","volume":"71","author":"Sidbury","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0017","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jaad.2010.04.027","article-title":"Enteric-coated mycophenolate sodium versus cyclosporin A as long-term treatment in adult patients with severe atopic dermatitis: a randomized controlled trial","volume":"64","author":"Haeck","year":"2011","journal-title":"J Am Acad Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0018","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1046\/j.1365-2133.2002.04989.x","article-title":"Azathioprine in severe adult atopic dermatitis: a double-blind, placebo-controlled, crossover trial","volume":"147","author":"Berth-Jones","year":"2002","journal-title":"Br J Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0019","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1016\/S0140-6736(06)68340-2","article-title":"Azathioprine dosed by thiopurine methyltransferase activity for moderate-to-severe atopic eczema: a double-blind, randomised controlled trial","volume":"367","author":"Meggitt","year":"2006","journal-title":"Lancet"},{"key":"2023011316192025600_bjd16317-bib-0020","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jaci.2011.03.024","article-title":"A randomized trial of methotrexate versus azathioprine for severe atopic eczema","volume":"128","author":"Schram","year":"2011","journal-title":"J Allergy Clin Immunol"},{"key":"2023011316192025600_bjd16317-bib-0021","doi-asserted-by":"crossref","first-page":"92S","DOI":"10.12788\/j.sder.2016.043","article-title":"Assessing the new and emerging treatments for atopic dermatitis","volume":"35","author":"Eichenfield","year":"2016","journal-title":"Semin Cutan Med Surg"},{"key":"2023011316192025600_bjd16317-bib-0022","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(16)30307-5","article-title":"Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting \u03b22 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial","volume":"388","author":"Wenzel","year":"2016","journal-title":"Lancet"},{"key":"2023011316192025600_bjd16317-bib-0023","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1001\/jama.2015.19330","article-title":"Effect of subcutaneous dupilumab on nasal polyp burden in patients with chronic sinusitis and nasal polyposis: a randomized clinical trial","volume":"315","author":"Bachert","year":"2016","journal-title":"JAMA"},{"key":"2023011316192025600_bjd16317-bib-0024","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"key":"2023011316192025600_bjd16317-bib-0025","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1016\/S0140-6736(17)31191-1","article-title":"Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial","volume":"389","author":"Blauvelt","year":"2017","journal-title":"Lancet"},{"key":"2023011316192025600_bjd16317-bib-0026","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1741-7015-8-18","article-title":"CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials","volume":"8","author":"Schulz","year":"2010","journal-title":"BMC Med"},{"key":"2023011316192025600_bjd16317-bib-0027","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","author":"Higgins","year":"2011"},{"key":"2023011316192025600_bjd16317-bib-0028","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1080\/10543400903242795","article-title":"An overview of practical approaches for handling missing data in clinical trials","volume":"19","author":"DeSouza","year":"2009","journal-title":"J Biopharm Stat"},{"key":"2023011316192025600_bjd16317-bib-0029","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1016\/j.jaad.2013.10.010","article-title":"Guidelines of care for the management of atopic dermatitis: section 1. Diagnosis and assessment of atopic dermatitis","volume":"70","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0030","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1016\/j.jaad.2014.03.023","article-title":"Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies","volume":"71","author":"Eichenfield","year":"2014","journal-title":"J Am Acad Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0031","doi-asserted-by":"crossref","first-page":"800","DOI":"10.1016\/j.jaci.2014.07.043","article-title":"The Harmonising Outcome Measures for Eczema (HOME) statement to assess clinical signs of atopic eczema in trials","volume":"134","author":"Schmitt","year":"2014","journal-title":"J Allergy Clin Immunol"},{"key":"2023011316192025600_bjd16317-bib-0032","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1016\/j.jaci.2007.08.011","article-title":"What are the best outcome measurements for atopic eczema? A systematic review","volume":"120","author":"Schmitt","year":"2007","journal-title":"J Allergy Clin Immunol"},{"key":"2023011316192025600_bjd16317-bib-0033","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.jaad.2015.09.062","article-title":"A systematic review of Investigator Global Assessment (IGA) in atopic dermatitis (AD) trials: many options, no standards","volume":"74","author":"Futamura","year":"2016","journal-title":"J Am Acad Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0034","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.det.2017.02.003","article-title":"The long-term course of atopic dermatitis","volume":"35","author":"Abuabara","year":"2017","journal-title":"Dermatol Clin"},{"key":"2023011316192025600_bjd16317-bib-0035","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s13063-015-1107-1","article-title":"Characterisation of trials where marketing purposes have been influential in study design: a descriptive study","volume":"17","author":"Barbour","year":"2016","journal-title":"Trials"},{"key":"2023011316192025600_bjd16317-bib-0036","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1016\/j.jid.2017.02.963","article-title":"More Atopic dermatitis trials using standard treatments as active comparators, please","volume":"137","author":"Wilkes","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0037","doi-asserted-by":"crossref","first-page":"1646","DOI":"10.1016\/j.jid.2017.04.009","article-title":"Quantitative evaluation of biologic therapy options for psoriasis: a systematic review and network meta-analysis","volume":"137","author":"Jabbar-Lopez","year":"2017","journal-title":"J Invest Dermatol"},{"key":"2023011316192025600_bjd16317-bib-0038","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.sder.2010.01.001","article-title":"Assessing long-term drug safety: lessons (re) learned from raptiva","volume":"29","author":"Seminara","year":"2010","journal-title":"Semin Cutan Med Surg"}],"container-title":["British Journal of Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fbjd.16317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/bjd.16317","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/bjd.16317","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/178\/4\/897\/47587820\/bjd0897.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/bjd\/article-pdf\/178\/4\/897\/47587820\/bjd0897.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,30]],"date-time":"2024-06-30T11:52:37Z","timestamp":1719748357000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/bjd\/article\/178\/4\/897\/6602458"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,1]]},"references-count":38,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2018,4,1]]},"published-print":{"date-parts":[[2018,4,1]]}},"URL":"https:\/\/doi.org\/10.1111\/bjd.16317","relation":{},"ISSN":["1365-2133","0007-0963"],"issn-type":[{"value":"1365-2133","type":"electronic"},{"value":"0007-0963","type":"print"}],"subject":[],"published-other":{"date-parts":[[2018,4,1]]},"published":{"date-parts":[[2018,4,1]]}}}